Premium
The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life
Author(s) -
Dunn Galvin A.,
McMahon S.,
Ponsonby A.L.,
Hsiao K.C.,
Tang M. L. K.
Publication year - 2018
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13330
Subject(s) - medicine , placebo , probiotic , quality of life (healthcare) , food allergy , allergy , randomized controlled trial , immunotherapy , oral immunotherapy , peanut allergy , analysis of variance , clinical trial , gastroenterology , immunology , alternative medicine , cancer , nursing , pathology , biology , bacteria , genetics
Background We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double‐blind, placebo‐controlled randomized trial. This study evaluated the impact of PPOIT on health‐related quality of life (HRQL). Method Fifty‐one participants (PPOIT 24; placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ‐PF) and Food Allergy Independent Measure (FAIM) at pre‐treatment, end‐of‐treatment and 3 months after end‐of‐treatment. A total of 42 participants (20 PPOIT; 22 placebo) completed measures at 12 months post‐treatment. Changes over time in PPOIT and placebo groups were examined by repeated‐measures analysis of variance and paired t tests. Results Probiotic and peanut oral immunotherapy was associated with significant improvement in FAQLQ‐PF ( F = 3.63, P = .02), with mean difference 0.8 at 3 months post‐treatment ( P = .05) and 1.3 at 12 months post‐treatment ( P = .005), exceeding the 0.5 minimal clinically important difference for FAQLQ‐PF. For FAIM, mean difference was 0.5 ( P = .03) at 3 months and 0.4 ( P = .04) at 12 months post‐treatment. In placebo group, post‐treatment FAQLQ and FAIM remained unchanged from pretreatment. Improvement in FAQLQ‐PF and FAIM scores related specifically to acquisition of sustained unresponsiveness rather than to receiving PPOIT treatment or participation in the trial. Conclusions Probiotic and peanut oral immunotherapy has a sustained beneficial effect on psychosocial impact of food allergy at 3 and 12 months after end‐of‐treatment. Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological well‐being was not negatively impacted. Improved HRQL was specifically associated with acquisition of sustained unresponsiveness.